Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes

被引：21

作者：

Tanabe, Masahiko ^{[1
,2
,3
]}

Ito, Yoshinori ^{[1
]}

Tokudome, Nahomi ^{[1
]}

Sugihara, Tsutomu ^{[1
]}

Miura, Hiroyoshi ^{[1
]}

Takahashi, Shunji ^{[1
]}

Seto, Yasuyuki ^{[3
,4
]}

Iwase, Takuji ^{[2
]}

Hatake, Kiyohiko ^{[1
]}

机构：

[1] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Med Oncol, Koto Ku, Tokyo 1358550, Japan

[2] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Breast Oncol, Koto Ku, Tokyo 1358550, Japan

[3] Univ Tokyo, Grad Sch Med, Dept Surg Metab Care & Endocrine Surg, Bunkyo Ku, Tokyo 1138655, Japan

[4] Univ Tokyo, Grad Sch Med, Dept Gastrointestinal Surg, Bunkyo Ku, Tokyo 1138655, Japan

来源：

BREAST CANCER | 2009年 / 16卷 / 04期

关键词：

Anthracycline; Metastatic breast cancer; Methotrexate; Mitomycin C; Taxanes; PHASE-III; REGIMEN; CAPECITABINE; VINORELBINE; VINBLASTINE; DOXORUBICIN; DOCETAXEL; THERAPY; TRIAL;

D O I：

10.1007/s12282-009-0093-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background Most patients with breast cancer need anthracycline-based chemotherapy regimens in the adjuvant setting, and an increasing number of them receive taxanes either in this setting or as first-line therapy for metastatic breast cancer (MBC). However, no standard chemotherapy has been fully established for MBC patients pretreated with anthracycline and taxanes. Methods We retrospectively reviewed the medical records of 48 patients with MBC who had been treated with chemotherapy combining mitomycin C and methotrexate (MMC/MTX), following treatment with anthracycline and taxanes. MMC was given at a dose of 8 mg/m(2) on day 1, and MTX of 60 mg/m(2) on day 1 and day 15. The cycle was repeated every 4 weeks. Results There were 11 partial responses (24%). The median time to progression was 4.8 months. The response rate of liver metastasis was 31%. Thrombocytopenia (grade 3) was observed in five patients (10%). Other toxicity was mild and manageable. Conclusions Our findings suggest that MMC/MTX could be an effective subsequent treatment for patients whose MBC has been pretreated with anthracycline and taxanes.

引用

页码：301 / 306

页数：6

共 26 条

[1] Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0
[2] CHEMOTHERAPY AND SURVIVAL IN ADVANCED BREAST-CANCER - THE INCLUSION OF DOXORUBICIN IN COOPER TYPE REGIMENS
AHERN, RP
SMITH, IE
EBBS, SR
[J]. BRITISH JOURNAL OF CANCER, 1993, 67 (04) : 801 - 805
[3] Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial
Biganzoli, L
Cufer, T
Bruning, P
Coleman, R
Duchateau, L
Calvert, AH
Gamucci, T
Twelves, C
Fargeot, P
Epelbaum, R
Lohrisch, C
Piccart, MJ
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (14) : 3114 - 3121
[4] CARCINOMA-ASSOCIATED HEMOLYTIC-UREMIC SYNDROME - A COMPLICATION OF MITOMYCIN-C CHEMOTHERAPY
CANTRELL, JE
PHILLIPS, TM
SCHEIN, PS
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (05) : 723 - 734
[5] CREECH RH, 1983, CANCER-AM CANCER SOC, V51, P1034, DOI 10.1002/1097-0142(19830315)51:6<1034::AID-CNCR2820510611>3.0.CO
[6] 2-B
[7] Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31,510 women
Fossati, R
Confalonieri, C
Torri, V
Ghislandi, E
Penna, A
Pistotti, V
Tinazzi, A
Liberati, A
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (10) : 3439 - 3460
[8] HORTOBAGYI GN, 1993, ONCOLOGY, V50, P1
[9] IZUO M, 1989, JPN J SURG, V19, P612
[10] Oral vinorelbine plus capecitabine (oral vincap) combination in patients with advanced breast cancer (ABC). A phase II study of the GOIM (Gruppo Oncologico dell'Italia Meridionale)
Lorusso, V.
Spada, M.
Giampaglia, M.
Misino, A.
Calabrese, R.
Latorre, A.
Monticelli, G.
Guida, M.
Sambiasi, D.
Colucci, G.
[J]. ANNALS OF ONCOLOGY, 2006, 17 : VII15 - VII17

← 1 2 3 →